Compare TK & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | DRTS |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | Bermuda | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1995 | 2021 |
| Metric | TK | DRTS |
|---|---|---|
| Price | $14.56 | $14.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.80 |
| AVG Volume (30 Days) | ★ 489.4K | 443.8K |
| Earning Date | 10-28-2026 | 11-19-2026 |
| Dividend Yield | ★ 7.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,235.59 |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $3.43 |
| 52 Week High | $14.93 | $15.79 |
| Indicator | TK | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 51.78 |
| Support Level | $13.06 | $13.73 |
| Resistance Level | $14.30 | $15.01 |
| Average True Range (ATR) | 0.44 | 0.59 |
| MACD | -0.08 | -0.07 |
| Stochastic Oscillator | 50.00 | 40.18 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.